Antineoplastics
1
Reactions 1347 - 16 Apr 2011 S Antineoplastics Fatal interstitial lung disease: case report A 64-year-old man with metastatic gastric cancer developed interstitial lung disease during treatment with FOLFOX-4 * [details not stated]; he subsequently died. The man was partially responsive to FOLFOX-4 chemotherapy, which was well tolerated with the exception of grade 1-2 peripheral neuropathy and grade 2 thrombocytopenia. Following his eighth cycle of FOLFOX-4, he developed a dry cough with progressive dyspnoea on exertion. Bilateral interstitial infiltrates were seen on a chest x-ray, and arterial blood gas analysis showed mild hypoxaemia. The man was hospitalised and received oxygen supplementation. Pneumonia was suspected, but he failed to respond to broad-spectrum antibiotics, and no infection could be identified on bronchoscopy or bronchoalveolar lavage. His symptoms worsened despite empirical antibiotic therapy with ciprofloxacin, cefepime and vancomycin. A CT scan revealed interstitial lung involvement predominantly affecting the peripheral lung, with thickening of interlobular septa, a ground-glass appearance and minor pleural effusion in both lungs. Interstitial lung disease was suspected. Despite treatment with high-dose corticosteroids, his symptoms worsened and he required intubation. He later died from refractory respiratory failure after 10 days of mechanical ventilation. His family declined an autopsy request. * FOLFOX-4 usually consists of fluorouracil, folinic acid [leucovorin] and oxaliplatin. Lim JH, et al. Interstitial lung disease associated with FOLFOX chemotherapy. Journal of Cancer Research and Therapeutics 6: 546-548, No. 4, Oct-Dec 2010. Available from: URL: http://dx.doi.org/10.4103/0973-1482.77066 - South Korea 803052701 1 Reactions 16 Apr 2011 No. 1347 0114-9954/10/1347-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved
Transcript of Antineoplastics
Reactions 1347 - 16 Apr 2011
SAntineoplastics
Fatal interstitial lung disease: case reportA 64-year-old man with metastatic gastric cancer
developed interstitial lung disease during treatment withFOLFOX-4* [details not stated]; he subsequently died.
The man was partially responsive to FOLFOX-4chemotherapy, which was well tolerated with theexception of grade 1-2 peripheral neuropathy and grade 2thrombocytopenia. Following his eighth cycle ofFOLFOX-4, he developed a dry cough with progressivedyspnoea on exertion. Bilateral interstitial infiltrates wereseen on a chest x-ray, and arterial blood gas analysisshowed mild hypoxaemia.
The man was hospitalised and received oxygensupplementation. Pneumonia was suspected, but he failedto respond to broad-spectrum antibiotics, and no infectioncould be identified on bronchoscopy or bronchoalveolarlavage. His symptoms worsened despite empiricalantibiotic therapy with ciprofloxacin, cefepime andvancomycin. A CT scan revealed interstitial lunginvolvement predominantly affecting the peripheral lung,with thickening of interlobular septa, a ground-glassappearance and minor pleural effusion in both lungs.Interstitial lung disease was suspected. Despite treatmentwith high-dose corticosteroids, his symptoms worsenedand he required intubation. He later died from refractoryrespiratory failure after 10 days of mechanical ventilation.His family declined an autopsy request.
* FOLFOX-4 usually consists of fluorouracil, folinic acid[leucovorin] and oxaliplatin.
Lim JH, et al. Interstitial lung disease associated with FOLFOX chemotherapy.Journal of Cancer Research and Therapeutics 6: 546-548, No. 4, Oct-Dec 2010.Available from: URL: http://dx.doi.org/10.4103/0973-1482.77066 - SouthKorea 803052701
1
Reactions 16 Apr 2011 No. 13470114-9954/10/1347-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved
